As of November 6, 2026, Xilio Therapeutics, Inc. is a publicly traded company (Nasdaq: XLO); its largest reported holder is Gilead Sciences, Inc., with 19.9% on Schedule 13G/A of February 12, 2026, then OrbiMed (9.99%). The largest insider holding is Gilead Sciences, Inc., a 10% owner, with 9,105,451 shares, per Form 4 of December 19, 2024 (Schedule 13G/A, February 12, 2026).
Is this your company?
About to sign with, pay or invest in Xilio Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Xilio Therapeutics, Inc. a real, registered company?
- Xilio Therapeutics, Inc. files with the SEC under CIK 1840233 (its SEC filings).
- Its shares are listed under the ticker XLO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Xilio Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names StemPoint Capital LP (filed 2026-08-14).
Who are Xilio Therapeutics, Inc.'s owners and officers?
Xilio Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Stempoint Capital LP | 9.5% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G, 2026-05-15 | Orbimed Advisors LLC | 9.99% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 9.9% |
| Schedule 13G/A, 2026-05-15 | Bcls Ii Equity Opportunities, LP | 9.99% |
| Schedule 13G/A, 2026-02-17 | Bcls Ii Equity Opportunities, LP | 8.5% |
| Schedule 13G/A, 2026-02-17 | Stempoint Capital LP | 8.4% |
| Schedule 13G/A, 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 6.7% |
| Schedule 13G/A, 2026-02-12 | Gilead Sciences, Inc. | 19.9% |
| Schedule 13G, 2025-12-11 | Coastlands Capital LP | 9.99% |
| Schedule 13G, 2025-11-14 | Stempoint Capital LP | 7.2% |
| Schedule 13G/A, 2025-11-14 | Point72 Asset Management, L.P. | 9.9% |
Questions about who owns Xilio Therapeutics, Inc.
Who owns Xilio Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Xilio Therapeutics, Inc.: Gilead Sciences, Inc. (19.9%, Schedule 13G/A, filed 2026-02-12), Orbimed Advisors LLC (9.99%, Schedule 13G, filed 2026-05-15), Bcls Ii Equity Opportunities, LP (9.99%, Schedule 13G/A, filed 2026-05-15), Coastlands Capital LP (9.99%, Schedule 13G, filed 2025-12-11) and Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15); 2 more are listed above.
Who are the largest shareholders of Xilio Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Xilio Therapeutics, Inc. on this page are Gilead Sciences, Inc. (19.9%), Orbimed Advisors LLC (9.99%) and Bcls Ii Equity Opportunities, LP (9.99%).
When did Gilead Sciences, Inc. buy into Xilio Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13G/A, filed 2026-02-12, reporting 19.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Xilio Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Xilio Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xilio Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Xilio Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , Inc., a 10% owner: 9,105,451 shares (Form 4, 2024-12-19).
- , the chief executive and president: 325,422 shares (5.6% of shares outstanding) (Form 4, 2026-01-05).
- , the chief medical officer: 33,250 shares (0.58% of shares outstanding) (Form 4, 2026-01-05).
- , the chief financial officer: 24,766 shares (0.43% of shares outstanding) (Form 4, 2026-01-05).
- , a director: 10,000 shares (0.17% of shares outstanding) (Form 4, 2026-03-30).
Shares outstanding: 5,782,511 as of 2026-03-18, from the company's latest SEC cover page.
How much has Xilio Therapeutics, Inc. raised?
No fundraising or offering filing from Xilio Therapeutics, Inc. is on file with us.
Keep reading
More on Xilio Therapeutics, Inc. and the records around it.
Xilio Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: C4 Therapeutics, Inc. (Oct 2025)
- StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026)
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), Arcus Biosciences, Inc. (Aug 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/xilio-therapeutics